Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL.

@article{Alves2012LeukemiainitiatingCO,
  title={Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL.},
  author={Catarina Castro Alves and Nadia Terziyska and Michaela Grunert and Sibylle G{\"u}ndisch and Ulrike B Graubner and Leticia Quintanilla-Martinez and Irmela Jeremias},
  journal={Blood},
  year={2012},
  volume={119 18},
  pages={4224-7}
}
Cancer stem cells represent the most important target cells for antitumor therapy. TRAIL (TNF-related apoptosis-inducing ligand) is a potential anticancer agent that induces apoptosis in a wide variety of tumor cells, but its ability to target cancer stem cells is currently unknown. Here we investigated whether TRAIL targets leukemia-initiating cells… CONTINUE READING